Cargando…

Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years

BACKGROUND: This study aimed to estimate vaccine effectiveness (VE) against omicron variant infection and severe corona virus disease 2019 (COVID-19) in children aged 5–11 years hospitalized with acute respiratory syndrome. METHODS: A test-negative, case–control analysis was conducted from February...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Eduardo A., Oliveira, Maria Christina L., Silva, Ana Cristina Simões e, Colosimo, Enrico A., Mak, Robert H., Vasconcelos, Mariana A., Silva, Ludmila R., Martelli, Daniella B., Pinhati, Clara C., Martelli-Júnior, Hercílio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010648/
https://www.ncbi.nlm.nih.gov/pubmed/36914907
http://dx.doi.org/10.1007/s12519-023-00699-6
_version_ 1784906219222204416
author Oliveira, Eduardo A.
Oliveira, Maria Christina L.
Silva, Ana Cristina Simões e
Colosimo, Enrico A.
Mak, Robert H.
Vasconcelos, Mariana A.
Silva, Ludmila R.
Martelli, Daniella B.
Pinhati, Clara C.
Martelli-Júnior, Hercílio
author_facet Oliveira, Eduardo A.
Oliveira, Maria Christina L.
Silva, Ana Cristina Simões e
Colosimo, Enrico A.
Mak, Robert H.
Vasconcelos, Mariana A.
Silva, Ludmila R.
Martelli, Daniella B.
Pinhati, Clara C.
Martelli-Júnior, Hercílio
author_sort Oliveira, Eduardo A.
collection PubMed
description BACKGROUND: This study aimed to estimate vaccine effectiveness (VE) against omicron variant infection and severe corona virus disease 2019 (COVID-19) in children aged 5–11 years hospitalized with acute respiratory syndrome. METHODS: A test-negative, case–control analysis was conducted from February 2022 to June 2022. We enrolled 6950 eligible children, including 1102 cases and 5848 controls. VE was calculated after immunization with one and two doses of BNT162b2 or CoronaVac. The outcomes were hospitalization with acute respiratory symptoms and detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19. The adjusted odds ratio for the association of prior vaccination and outcomes was used to estimate VE. RESULTS: For fully vaccinated children, the overall estimated VE against hospitalization with SARS-CoV-2 infection was 42% [95% confidence interval (CI) 26 to 54]. VE peaked at 29–42 days (67%, 95% CI 40% to 82%) and then declined to 19% (95% CI, − 20% to 45%) at 57–120 days after the second dose. The BNT162b2 vaccine had a similar VE against hospitalization with SARS-CoV-2 infection (45%, 95% CI, 20 to 61) compared to the CoronaVac vaccine (40%, 95% CI, 17% to 56%). Among cases, 56 (5%) children died; 53 (94.6%) were not fully vaccinated. For cases, the two-dose schedule effectiveness against ICU admission, need for invasive ventilation, severe illness, and death were 10% (95% CI, − 54%–45%), 22% (95% CI − 70%–68%), 12% (95% CI, − 62%–52%), and 16% (95% CI, − 77%–75%), respectively. CONCLUSIONS: For hospitalized children aged 5–11 years during the omicron-predominant period in Brazil, two doses of both vaccines had moderate effectiveness against hospitalization with acute respiratory symptoms and SARS-CoV-2 infection and offered limited protection against endpoints of COVID-19 severity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12519-023-00699-6.
format Online
Article
Text
id pubmed-10010648
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-100106482023-03-14 Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years Oliveira, Eduardo A. Oliveira, Maria Christina L. Silva, Ana Cristina Simões e Colosimo, Enrico A. Mak, Robert H. Vasconcelos, Mariana A. Silva, Ludmila R. Martelli, Daniella B. Pinhati, Clara C. Martelli-Júnior, Hercílio World J Pediatr Original Article BACKGROUND: This study aimed to estimate vaccine effectiveness (VE) against omicron variant infection and severe corona virus disease 2019 (COVID-19) in children aged 5–11 years hospitalized with acute respiratory syndrome. METHODS: A test-negative, case–control analysis was conducted from February 2022 to June 2022. We enrolled 6950 eligible children, including 1102 cases and 5848 controls. VE was calculated after immunization with one and two doses of BNT162b2 or CoronaVac. The outcomes were hospitalization with acute respiratory symptoms and detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19. The adjusted odds ratio for the association of prior vaccination and outcomes was used to estimate VE. RESULTS: For fully vaccinated children, the overall estimated VE against hospitalization with SARS-CoV-2 infection was 42% [95% confidence interval (CI) 26 to 54]. VE peaked at 29–42 days (67%, 95% CI 40% to 82%) and then declined to 19% (95% CI, − 20% to 45%) at 57–120 days after the second dose. The BNT162b2 vaccine had a similar VE against hospitalization with SARS-CoV-2 infection (45%, 95% CI, 20 to 61) compared to the CoronaVac vaccine (40%, 95% CI, 17% to 56%). Among cases, 56 (5%) children died; 53 (94.6%) were not fully vaccinated. For cases, the two-dose schedule effectiveness against ICU admission, need for invasive ventilation, severe illness, and death were 10% (95% CI, − 54%–45%), 22% (95% CI − 70%–68%), 12% (95% CI, − 62%–52%), and 16% (95% CI, − 77%–75%), respectively. CONCLUSIONS: For hospitalized children aged 5–11 years during the omicron-predominant period in Brazil, two doses of both vaccines had moderate effectiveness against hospitalization with acute respiratory symptoms and SARS-CoV-2 infection and offered limited protection against endpoints of COVID-19 severity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12519-023-00699-6. Springer Nature Singapore 2023-03-13 /pmc/articles/PMC10010648/ /pubmed/36914907 http://dx.doi.org/10.1007/s12519-023-00699-6 Text en © Children's Hospital, Zhejiang University School of Medicine 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Oliveira, Eduardo A.
Oliveira, Maria Christina L.
Silva, Ana Cristina Simões e
Colosimo, Enrico A.
Mak, Robert H.
Vasconcelos, Mariana A.
Silva, Ludmila R.
Martelli, Daniella B.
Pinhati, Clara C.
Martelli-Júnior, Hercílio
Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
title Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
title_full Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
title_fullStr Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
title_full_unstemmed Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
title_short Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
title_sort effectiveness of bnt162b2 and coronavac vaccines against omicron in children aged 5 to 11 years
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010648/
https://www.ncbi.nlm.nih.gov/pubmed/36914907
http://dx.doi.org/10.1007/s12519-023-00699-6
work_keys_str_mv AT oliveiraeduardoa effectivenessofbnt162b2andcoronavacvaccinesagainstomicroninchildrenaged5to11years
AT oliveiramariachristinal effectivenessofbnt162b2andcoronavacvaccinesagainstomicroninchildrenaged5to11years
AT silvaanacristinasimoese effectivenessofbnt162b2andcoronavacvaccinesagainstomicroninchildrenaged5to11years
AT colosimoenricoa effectivenessofbnt162b2andcoronavacvaccinesagainstomicroninchildrenaged5to11years
AT makroberth effectivenessofbnt162b2andcoronavacvaccinesagainstomicroninchildrenaged5to11years
AT vasconcelosmarianaa effectivenessofbnt162b2andcoronavacvaccinesagainstomicroninchildrenaged5to11years
AT silvaludmilar effectivenessofbnt162b2andcoronavacvaccinesagainstomicroninchildrenaged5to11years
AT martellidaniellab effectivenessofbnt162b2andcoronavacvaccinesagainstomicroninchildrenaged5to11years
AT pinhaticlarac effectivenessofbnt162b2andcoronavacvaccinesagainstomicroninchildrenaged5to11years
AT martellijuniorhercilio effectivenessofbnt162b2andcoronavacvaccinesagainstomicroninchildrenaged5to11years